A chemotherapeutic drug-polymer conjugate capable of triggering active transcellular transport and its preparation method and application
By designing multifunctional dual-response nanoparticles, active transcellular transport of chemotherapy drugs for pancreatic cancer and regulation of the tumor microenvironment were achieved, solving the delivery and penetration problems of chemotherapy and immunotherapy for pancreatic cancer, activating anti-tumor immune responses, and improving treatment efficacy.
Patent Information
- Application Number
- CN202310102978.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-02-13
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-02-13
AI Technical Summary
Chemotherapy and immunotherapy are ineffective for pancreatic cancer, mainly because the dense matrix restricts the delivery of chemotherapeutic drugs and the recruitment of immune cells, traditional nanomedicines have difficulty penetrating deeply, and the tumor microenvironment inhibits anti-tumor immune responses.
A multifunctional dual-response nanoparticle was designed to achieve active transcellular transport of chemotherapeutic drugs and regulation of the tumor microenvironment through a responsive prodrug-polymer conjugate containing PODEA and PHMI blocks. Utilizing the high affinity of PODEA and the immune-activating ability of PHMI, the nanoparticle responds to the slightly acidic environment and reducing substances to release drugs, thereby activating the STING pathway and promoting anti-tumor immune responses.
Nanoparticles can deeply penetrate tumor sites, selectively release chemotherapy drugs, activate anti-tumor immune responses, reduce non-tumor cell toxicity, improve the efficacy of chemotherapy, and enhance the efficacy of immunotherapy.
Smart Images

Figure CN116370648B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and specifically relates to a chemotherapy drug-polymer conjugate capable of triggering active transcellular transport, as well as a preparation method and application thereof. Background Art
[0002] The highly dense stroma of pancreatic cancer limits the delivery and penetration of chemotherapy drugs, leading to chemoresistance. Furthermore, the dense stroma hinders the recruitment of immune cells. Complex tumor-stroma-immune cell crosstalk shapes an immunosuppressive tumor microenvironment, resulting in poor clinical efficacy of both chemotherapy and immunotherapy for pancreatic cancer.
[0003] The formulation of drugs into nanoformulations has been widely explored as a viable strategy to overcome the delivery dilemma. Traditional anti-tumor delivery strategies typically focus on overcoming the delivery barrier constructed by the tumor extracellular matrix by regulating the particle size or surface potential of nanomedicines, while ignoring the barrier function of the cells themselves. This often leads to limited penetration of nanomedicines in tumor tissues, making it difficult for nanomedicines to be delivered to deep-seated tumor cells. Therefore, rationally designing nanomedicines to trigger active transcellular transport to enhance the delivery efficiency of nanomedicines is a feasible strategy for addressing the delivery of anti-pancreatic cancer drugs.
[0004] Poly (2-(1-azacycloheptyl)ethyl methacrylate) (PHMI), which has a cyclic tertiary amine structure, exhibits STING-dependent immune activation, triggering sustained cytokine expression and comprehensively promoting anti-immune responses. At the same time, as a major driver of connective tissue hyperplasia in pancreatic cancer, focal adhesion kinase (FAK) serves as a key molecular fulcrum for reshaping the tumor microenvironment, affecting the infiltration of drugs and immune cells into deep tumors. Because PHMI can also respond to the weak acidity of the tumor microenvironment, achieving a hydrophobic to hydrophilic transition, it can specifically release FAK inhibitors in the tumor microenvironment, modulating the microenvironment and synergistically promoting anti-tumor immune responses. Summary of the Invention
[0005] To address the aforementioned challenges in pancreatic cancer treatment, the present invention, building on existing technologies, has designed and prepared a multifunctional, dual-responsive nanoparticle capable of triggering active transcellular transport for the co-delivery of chemotherapeutic drugs and tumor microenvironment modulators. The nanoparticle is constructed from a responsive prodrug-polymer conjugate. The responsive prodrug is gemcitabine containing a responsive disulfide bond. The polymer conjugate comprises a poly (diethylaminoethyl N-oxymethacrylate) (PODEA) block and a PHMI block.
[0006] PODEA shows high affinity for phospholipids and weak affinity for proteins, which can effectively prolong the circulation time of nanoparticles; at the same time, its unique affinity enables PODEA to reversibly bind to the cell membrane and induce adsorption-mediated active transcellular transport, thereby promoting the extravasation and deep penetration of nanoparticles in the tumor site.
[0007] To prevent the highly toxic chemotherapy drug from being taken up by non-tumor cells and potentially causing side effects, the present invention modifies the chemotherapy drug gemcitabine into a prodrug containing a responsive disulfide bond and then couples it to the polymer backbone. When the prodrug is taken up by tumor cells, high intracellular concentrations of glutathione break down the disulfide bonds, releasing free gemcitabine, which selectively and efficiently kills the tumor. Conversely, gemcitabine is not released into non-tumor cells, thus avoiding side effects caused by non-selective toxicity.
[0008] The PHMI block can respond to the slightly acidic tumor microenvironment by switching between hydrophilic and hydrophobic properties, specifically releasing microenvironmental modulators. Furthermore, upon cellular uptake, PHMI activates STING, promoting cytokine expression and stimulating anti-tumor immune responses. This design integrates strategies such as promoting deep drug penetration, modulating the tumor microenvironment, selectively releasing cytotoxic drugs, and activating anti-tumor immune responses into a single nano-delivery platform, offering a promising combination therapy for pancreatic cancer.
[0009] In order to achieve the above object, the present invention provides the following technical solutions:
[0010] The present invention provides a chemotherapeutic drug-polymer conjugate that can trigger active transcellular transport. The structural formula of the conjugate is shown in Formula I:
[0011]
[0012] Wherein, X is a chemotherapy drug having an amino group or a hydroxyl group, preferably gemcitabine, paclitaxel, doxorubicin or SN-38; n:z=1:(1-4); n=10-40, m=2-8;
[0013] The conjugate can induce polymerization of STING monomers.
[0014] The present invention also provides a method for preparing the above-mentioned chemotherapeutic drug-polymer conjugate capable of triggering active transcellular transport, comprising the following steps:
[0015] (1) 2,2'-dithiodiethanol and methacryloyl chloride are reacted at room temperature in the presence of an acid binding agent to obtain a colorless oily product SS-MA;
[0016] (2) reacting the SS-MA described in step (1) with 4-nitrophenyl chloroformate in the presence of a catalyst and an acid binding agent at room temperature to obtain a light yellow oily product SS-MA-PNP;
[0017] (3) reacting the SS-MA-PNP described in step (2) with gemcitabine whose hydroxyl group is protected by tert-butyldimethylsilyl chloride (TBS) in the presence of a catalyst and an acid binding agent at room temperature to obtain a light yellow solid product, Gem-SS-MA-TBS;
[0018] (4) removing TBS from the Gem-SS-MA-TBS described in step (3) in an ice bath under the action of acetic acid and tetrabutylammonium fluoride to obtain a white solid product, Gem-SS-MA;
[0019] (5) Acylation reaction of methacryloyl chloride with 2-(hexamethyleneimino)ethanol in the presence of an acid-binding agent yields a yellow oily product, HMI-MA;
[0020] (6) 2-(N,N-diethylamino)ethyl methacrylate was polymerized to obtain a light yellow viscous liquid product, PDEA; PDEA was dissolved in a 30% H2O2 solution and shaken at room temperature to obtain a flocculent white solid product, PODEA;
[0021] (7) The Gem-SS-MA described in step (4), the HMI-MA described in step (5), and the PODEA described in step (6) are polymerized to obtain a light yellow flocculent solid product PODEA-Gem-HMI, which is the above-mentioned chemotherapy drug-polymer conjugate that can trigger active transcellular transport.
[0022] Preferably, the catalyst is 4-dimethylaminopyridine, and the acid binding agent is triethylamine.
[0023] Preferably, in step (1), 2,2'-dithiodiethanol and triethylamine are first dissolved in an organic solvent and cooled to 0°C, and a mixture of methacryloyl chloride and the organic solvent is added dropwise within 30 minutes. After 1 hour, the reaction system is returned to room temperature and the stirring reaction is continued for 12 hours. Further preferably, the molar ratio of 2,2'-dithiodiethanol, triethylamine, and methacryloyl chloride is 1:(1-2):(1-1.5).
[0024] Preferably, in step (2), SS-MA, 4-dimethylaminopyridine, and triethylamine are first dissolved in an organic solvent and cooled to 0°C. A mixture of 4-nitrophenylchloroformate and the organic solvent is added dropwise over 1 hour. After 1 hour, the reaction system is returned to room temperature and the stirring reaction is continued for 12 hours. Further preferably, the molar ratio of SS-MA, 4-nitrophenylchloroformate, 4-dimethylaminopyridine, and triethylamine is 1:(1-1.5):(0.01-0.05):(1.2-1.8).
[0025] Preferably, the molar ratio of SS-MA-PNP, gemcitabine whose hydroxyl group is protected by tert-butyldimethylsilyl chloride, 4-dimethylaminopyridine, and triethylamine in step (3) is 1:(1-2):(0.01-0.05):(1-2.5). Preferably, SS-MA-PNP, 4-dimethylaminopyridine, and triethylamine are first dissolved in dichloromethane and cooled to 0°C. A mixture of gemcitabine whose hydroxyl group is protected by tert-butyldimethylsilyl chloride and dichloromethane is added dropwise over 30 minutes. After 1 hour, the reaction system is returned to room temperature and the reaction is continued with stirring for 6 hours.
[0026] Preferably, in step (4), Gem-SS-MA-TBS is first dissolved in an organic solvent, and then a mixture of acetic acid, tetrabutylammonium fluoride, and the organic solvent is added, and the mixture is stirred in an ice bath for 5 hours. The acetic acid acts as a base to neutralize the reaction; the tetrabutylammonium fluoride acts to break the silicon-oxygen bond and remove the TBS protecting group.
[0027] Preferably, in step (4), the molar ratio of Gem-SS-MA-TBS, acetic acid, and tetrabutylammonium fluoride is 1:(2-8):(2-5).
[0028] Preferably, the mass ratio of 2-(hexamethyleneimino)ethanol, methacryloyl chloride, and triethylamine in step (5) is 1:(1-1.5):(1-2). Preferably, in step (5), 2-(hexamethyleneimino)ethanol and triethylamine are first dissolved in an organic solvent and cooled to 0°C. A mixture of methacryloyl chloride and the organic solvent is added dropwise over 30 minutes. After 1 hour, the reaction system is returned to room temperature and the reaction is continued with stirring for 12 hours.
[0029] Preferably, in step (6), 2-(N,N-diethylamino)ethyl methacrylate is subjected to ATRP polymerization reaction at 40°C with ethyl 2-bromoisobutyrate as an initiator, in the presence of a catalytic system of 2,2'-bipyridine and cuprous bromide, and in methanol as a solvent, for 12 hours. Further preferably, the mass ratio of ethyl 2-bromoisobutyrate, 2-(N,N-diethylamino)ethyl methacrylate, 2,2'-bipyridine, and cuprous bromide is 1:(10-60):(0.5-3):(0.2-1).
[0030] Preferably, in step (7), the Gem-SS-MA described in step (4), the HMI-MA described in step (5), and the PODEA described in step (6) are reacted at 40°C for 12 hours in a 2,2'-bipyridine and cuprous bromide catalytic system to perform ATRP polymerization, and the solvent is N,N-dimethylformamide. Further preferably, the molar ratio of PODEA, HMI-MA, and Gem-SS-MA is (3-8):(5-20):1, and the molar ratio of PODEA, 2,2'-bipyridine, and cuprous bromide is 1:(0.5-3):(0.2-1).
[0031] Preferably, the organic solvent is tetrahydrofuran.
[0032] The present invention also provides drug-loaded polymer nanoparticles prepared from the above-mentioned chemotherapy drug-polymer conjugate that can trigger active transcellular transport. The nanoparticles also encapsulate small molecule hydrophobic FAK inhibitors with a drug loading of 2%-20%; the nanoparticles have a particle size of 30-150nm.
[0033] Preferably, the small molecule hydrophobic FAK inhibitor is defatinib, PND-1186, PF-431396, PF-562271, PF-573228 or TAE226.
[0034] The conjugates and nanoparticles described herein can trigger adhesion-mediated active transcellular transport and release chemotherapeutic drugs in response to reducing substances, such as glutathione or dithiothreitol. The nanoparticles can respond to a slightly acidic environment (pH 5.0–6.8) to undergo protonation and hydrophilic-hydrophobic conversion, and release the encapsulated hydrophobic drug. In the conjugates, the polymer block that can trigger active transcellular transport is poly (diethylaminoethyl N-oxymethacrylate) with a molecular weight of 2000-8000; the polymer block that can respond to the slightly acidic environment in tumor tissue is poly (2-(1-azacycloheptyl)ethyl methacrylate) with a molecular weight of 3000-10000; and the polymer block that can trigger the polymerization of STING monomers is still poly (2-(1-azacycloheptyl)ethyl methacrylate).
[0035] The present invention also provides a method for preparing the drug-loaded polymer nanoparticles capable of triggering active transcellular transport, comprising the following steps:
[0036] The above-mentioned chemotherapy drug-polymer conjugate PODEA-Gem-HMI that can trigger active transcellular transport and the small molecule hydrophobic FAK inhibitor are dissolved in a polar organic solvent, then dropped into PBS buffer under vigorous stirring, and continued to be vigorously stirred. After centrifugation and dialysis, drug-loaded polymer nanoparticles that can trigger active transcellular transport are obtained.
[0037] Preferably, the stirring speed is >150 rpm.
[0038] The drug-loaded polymer nanoparticles of the present invention, which can trigger active transcellular transport, are composed of a chemotherapy drug molecule, a microenvironment-regulating drug molecule, a disulfide bond, and a poly-N-oxide-poly-seven-membered tertiary amine block copolymer. The chemotherapy drug molecule is gemcitabine; the microenvironment-regulating molecule is the FAK small molecule inhibitor defatinib; the nanoparticles stimulate release of the drug by the high concentration of glutathione in tumor cells, and the site of response stimulation is the disulfide bond.
[0039] In the present invention, the gemcitabine prodrug is first coupled to a disulfide bond-containing compound via a carbamate bond.
[0040] In the present invention, the nanoparticles are prepared by dissolving a polymer and a microenvironment regulation inhibitor in a nano polar organic solvent (methanol, acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide), and then dropping the solvent into an aqueous phase under vigorous stirring.
[0041] Compared with the prior art, the present invention has the following advantages:
[0042] (1) The nanoparticles of the present invention are easy to prepare, have strong compatibility, and good stability, and are suitable for the selective delivery of various hydrophobic chemotherapy drugs or small molecule inhibitors.
[0043] (2) The nanoparticles of the present invention have a long circulation time in the body and do not show obvious systemic toxicity after multiple administrations.
[0044] (3) Compared with traditional intravenous administration, the nanoparticles of the present invention have obvious tumor accumulation and deep tumor penetration capabilities, which can effectively deliver drugs to deep tumors, play a chemotherapy sensitization role, and reduce systemic toxicity.
[0045] (4) The nanoparticles of the present invention can effectively regulate the tumor microenvironment and activate the STING pathway, promote downstream signal transduction, and activate anti-tumor immune responses. BRIEF DESCRIPTION OF THE DRAWINGS
[0046] Figure 1 Synthetic route for reduction-responsive disulfide-bonded gemcitabine prodrugs.
[0047] Figure 2 This is the synthetic route of PODEA-Gem-HMI polymer.
[0048] Figure 3 Microscopic morphology, particle size and distribution of PODEA-Gem-HMI polymer nanoparticles; a) particle size and PDI data measured by DLS, b) TEM image of nanoparticles.
[0049] Figure 4The pH-responsive properties of PODEA-Gem-HMI polymer nanoparticles. After incubation in PBS (pH 6.8), a) DLS-measured particle size and PDI data, b) TEM image, c) nanoparticle size change before and after incubation, d) nanoparticle surface zeta potential change before and after incubation, e) I-quenching assay to verify nanoparticle dissociation, and f) release kinetics of encapsulated defatinib.
[0050] Figure 5 To investigate the kinetics of gemcitabine release from PODEA-Gem-HMI polymer nanoparticles in response to a reducing environment.
[0051] Figure 6 This is an investigation of the tumor penetration ability of PODEA-Gem-HMI polymer nanoparticles in the Pan02 tumor sphere model.
[0052] Figure 7 The protein expressions of STING, pSTING and pTBK in primary macrophages at different time points after treatment with PODEA-HMI.
[0053] Figure 8 Flow cytometric analysis of DC maturation after treatment of bone marrow-derived DCs with different free drugs / nanoparticles for 24 h. DETAILED DESCRIPTION
[0054] The present invention will be further described below in conjunction with specific embodiments, and the advantages and features of the present invention will become clearer as the description proceeds. However, the embodiments are merely exemplary and do not limit the scope of the present invention in any way. It should be understood by those skilled in the art that the details and forms of the technical solutions of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, and such modifications and replacements fall within the scope of protection of the present invention.
[0055] Example 1
[0056] A chemotherapeutic drug-polymer conjugate capable of triggering active transcellular transport and a preparation method thereof, the preparation method comprising the following steps:
[0057] (1) Synthesis of reduction-responsive disulfide-bonded gemcitabine prodrugs
[0058] 1) Weigh 2.52 g of 2,2'-dithiodiethanol and 3.4 mL of triethylamine and dissolve them in 20 mL of anhydrous tetrahydrofuran and cool to 0°C. Add a solution of 1.62 g of methacryloyl chloride in anhydrous tetrahydrofuran dropwise over 30 minutes. After 1 hour, return the reaction system to room temperature and continue stirring for 12 hours. The reaction proceeds as shown in Formula II. Monitor the reaction by thin-layer chromatography (ethyl acetate:petroleum ether = 1:3). Upon completion, dilute the reaction with ethyl acetate and wash with saturated Na2CO3 solution and brine. Collect the organic layer, dry it over anhydrous sodium sulfate, and remove the solvent by rotary evaporation. The crude product is purified by silica gel column chromatography (ethyl acetate:petroleum ether = 1:3) to obtain SS-MA as a colorless oil.
[0059]
[0060] 2) Dissolve 400 mg of SS-MA, 6 mg (catalytic amount) of 4-dimethylaminopyridine (DMAP), and 0.32 mL of triethylamine in 10 mL of anhydrous tetrahydrofuran and cool to 0°C. Add a solution of 460 mg of phenyl 4-nitrochloroformate in anhydrous THF dropwise over 1 hour. After 1 hour, return the reaction system to room temperature and continue stirring for 12 hours. The reaction process is shown in Formula III. Monitor the reaction by thin-layer chromatography (ethyl acetate:petroleum ether = 1:4). After completion of the reaction, dilute the reaction solution with dichloromethane, then wash with saturated NH4Cl solution and saturated brine. Collect the organic layer, dry it over anhydrous sodium sulfate, and remove the solvent by rotary evaporation. The crude product is purified by silica gel column chromatography (ethyl acetate:petroleum ether = 1:4) to obtain SS-MA-PNP as a pale yellow oil.
[0061]
[0062] 3) Dissolve 200 mg of SS-MA-PNP, 2 mg (catalytic amount) of 4-dimethylaminopyridine, and 0.10 mL of triethylamine in 5 mL of anhydrous dichloromethane and cool to 0°C. Add a dichloromethane solution containing 300 mg of gemcitabine protected with tert-butyldimethylsilyl chloride (TBS) dropwise over 30 minutes. After 1 hour, return the reaction system to room temperature and continue stirring for 6 hours. The reaction process is as shown in Formula IV. The crude product is purified on a silica gel column (ethyl acetate:petroleum ether = 1:2) to obtain Gem-SS-MA-TBS as a light yellow solid.
[0063]
[0064] 4) 100 mg of Gem-SS-MA-TBS was dissolved in 5 mL of anhydrous tetrahydrofuran, and 50 μL of acetic acid and 500 μL of tetrabutylammonium fluoride solution (TBAF, 1 M in anhydrous tetrahydrofuran) were added. The mixture was stirred in an ice bath for 5 h. The reaction process is shown in Formula V. After removing the solvent, the crude product was purified by silica gel column (methanol: dichloromethane = 1:4) to obtain a white solid product, the reduction-responsive gemcitabine prodrug containing a disulfide bond, Gem-SS-MA. The overall synthetic route of Gem-SS-MA is shown in FIG. Figure 1 As shown in .
[0065]
[0066] (2) Synthesis of 2-(1-azepanyl)ethyl methacrylate
[0067] Dissolve 3 g of 2-(hexamethyleneimino)ethanol and 6 mL of triethylamine in 20 mL of anhydrous tetrahydrofuran and cool to 0°C. Add 3.38 g of methacryloyl chloride in anhydrous tetrahydrofuran dropwise over 30 minutes. After 1 hour, return the reaction system to room temperature and continue stirring for 12 hours. The reaction progress is shown in Formula VI. Monitor the reaction by thin-layer chromatography (ethyl acetate:petroleum ether = 1:4). Upon completion, dilute the reaction solution with ethyl acetate and then wash with saturated Na2CO3 solution and saturated brine. Collect the organic layer, dry it over anhydrous sodium sulfate, and remove the solvent by rotary evaporation to obtain 2-(1-azacycloheptyl)ethyl methacrylate (HMI-MA) as a yellow oil.
[0068]
[0069] (3) Synthesis of poly (diethylaminoethyl N-oxymethacrylate)
[0070] 1) Dissolve 35.1 mg of ethyl 2-bromoisobutyrate, 2 g of 2-(N,N-diethylamino)ethyl methacrylate, and 17.4 mg of 2,2'-bipyridine in 5 mL of anhydrous methanol and add the mixture to a Schlenk tube. The reaction mixture was deoxygenated by repeated freeze-drying with liquid nitrogen five times. Then, under nitrogen, 8 mg of cuprous bromide was added to the Schlenk tube. The polymerization reaction was carried out at 40°C for 12 hours, as shown in Formula VII. Upon completion, the Schlenk tube was opened to introduce oxygen and quench the reaction by diluting with 50 mL of anhydrous tetrahydrofuran. The mixture was passed through an alumina column to remove copper, concentrated under reduced pressure, and precipitated with pre-chilled n-hexane to yield the product, PDEA, as a pale yellow, viscous liquid.
[0071]
[0072] 2) Dissolve 500 mg of PDEA in 5 mL of 30% H₂O₂ solution and shake at 100 rpm at room temperature for 4 hours. The reaction proceeds as described in Formula VIII. The reaction solution is dialyzed against deionized water (3.5k MWCO) for 24 hours to remove unreacted H₂O₂. Lyophilize to obtain a flocculent white solid product, poly (diethylaminoethyl methacrylate N-oxide), PODEA.
[0073]
[0074] (4) 200 mg of PODEA, 300 mg of HMI-MA, 100 mg of Gem-SS-MA and 8.7 mg of 2,2'-bipyridine were dissolved in 3 mL of anhydrous N,N-dimethylformamide and transferred to a Schlenk tube. The reaction solution was deoxygenated by repeated freeze-drying cycles with liquid nitrogen for five times, and then 4 mg of cuprous bromide was added to the Schlenk tube under nitrogen protection. The polymerization reaction was carried out at 40°C for 12 hours, and the reaction process was as shown in Formula IX. After completion, oxygen was introduced by opening the Schlenk tube and the reaction was quenched by diluting with 50 mL of anhydrous tetrahydrofuran. The mixture was passed through an alumina column to remove copper, concentrated under reduced pressure, and then dialyzed with N,N-dimethylformamide and deionized water (3.5k MWCO) for 24 hours respectively. Freeze-dried to obtain a light yellow flocculent solid product PODEA-Gem-HMI. The synthesis of PODEA and the overall synthetic route for preparing PODEA-Gem-HMI from PODEA are shown in Figure 9. Figure 2 As shown in .
[0075]
[0076] A method for preparing drug-loaded polymer nanoparticles capable of triggering active transcellular transport comprises the following steps:
[0077] 30 mg of PODEA-Gem-HMI polymer and 3 mg of defatinib were dissolved in 1 mL of dimethyl sulfoxide and added dropwise to 5 mL of PBS buffer over 10 minutes under vigorous stirring (stirring speed >150 rpm). Vigorous stirring was continued for 20 minutes. Centrifugation was performed at 6000 g for 30 minutes using a 100 kDa ultrafiltration tube and replaced with fresh PBS buffer to remove the organic solvent. This was repeated three times, resulting in a final nanoparticle volume of 1 mL.
[0078] Particle size and distribution of PODEA-Gem-HMI polymer nanoparticles ( Figure 3 a) Microscopic morphology ( Figure 3 b) If Figure 3 As shown in Figure 3 It can be seen that under physiological conditions (pH 7.4), the average particle size of the nanoparticles is 41 nm, the distribution is uniform and the morphology is round (the polydispersity coefficient is 0.108).
[0079] The pH response characteristics of PODEA-Gem-HMI polymer nanoparticles were analyzed. Figure 4 shown.
[0080] Among them, Figure a shows the size change and particle size distribution of nanoparticles after incubation in a slightly acidic environment (pH 6.8). It can be seen from Figure a that the size of the nanoparticles increases significantly in a slightly acidic environment, and the distribution uniformity decreases significantly (the polydispersity coefficient increases to 0.825).
[0081] Figure b is a TEM image of nanoparticles in a slightly acidic environment. It can be seen from Figure b that in a slightly acidic environment, the nanoparticles undergo a hydrophilic-hydrophobic transition, resulting in disintegration, forming a disordered loose cluster structure.
[0082] Figure c shows the size changes of nanoparticles under in vitro simulated physiological environment (pH 7.4) and tumor slightly acidic environment (pH 6.8). It can be seen from Figure c that the particle size of nanoparticles increases significantly in the slightly acidic environment.
[0083] Figure d shows the change in the surface ζ potential of the nanoparticles in an in vitro simulated physiological environment and a slightly acidic tumor environment. It can be seen from Figure d that the surface potential of the nanoparticles changes from negative to positive, reflecting the charge reversal characteristic, which is conducive to increasing cellular uptake.
[0084] Figure e shows the quenching effect of iodide ions on FITC coupled to the hydrophobic core of the nanoparticles at pH 7.4 and pH 6.8. It can be seen from Figure e that at pH 6.8, the FITC inside the nanoparticles is exposed and quenched by iodide ions, confirming the pH-responsive hydrophilic-hydrophobic conversion ability of the nanoparticles.
[0085] Figure f shows the pH-responsive release kinetics of encapsulated defatinib. It can be seen from Figure f that the nanoparticles can selectively release defatinib in a slightly acidic environment, and about 80% of the encapsulated drug can be released within 8 hours.
[0086] The release kinetics of gemcitabine from PODEA-Gem-HMI polymer nanoparticles in response to a reducing environment were investigated. Figure 5 As shown: Nanoparticles can specifically release gemcitabine in response to a reducing environment, and exhibit the characteristics of dual dependence on the intensity and time of reducing conditions.
[0087] The tumor penetration ability of PODEA-Gem-HMI polymer nanoparticles was investigated in the Pan02 tumor sphere model. Figure 6As shown, PODEA nanoparticles have significantly stronger tumor sphere penetration than PEG nanoparticles. Pretreatment with the macropinocytosis inhibitor wortmannin significantly weakened tumor sphere penetration, demonstrating that nanoparticle uptake is primarily via the macropinocytosis pathway. Furthermore, treatment with the exocytosis inhibitors brefeldin A or Exo1 also significantly reduced the tumor sphere penetration of PODEA nanoparticles, indicating that active transcellular transport is an important pathway promoting PODEA nanoparticle tumor sphere penetration.
[0088] Figure 7 The protein expression of STING, pSTING and pTBK in primary macrophages at different time points after treatment with PODEA-HMI: the nanoparticles have sustained STING activation ability, and high levels of pSTING and pTBK protein expression are still present 48 hours after administration.
[0089] Figure 8 Flow cytometric analysis of DC maturation after 24 h of treatment of bone marrow-derived DC cells with different free drugs / nanoparticles showed that the nanoparticles had similar DC activation ability to the positive control lipopolysaccharide, and had stronger DC activation ability than the small molecule STING agonist (DXMAA).
Claims
1. A chemotherapeutic drug-polymer conjugate that can trigger active transcellular transport, It is characterized in that The conjugate structure is shown in Formula I: Formula I Wherein, X is gemcitabine; n:z=1:(1-4); n=10-40, m=2-8; and the conjugate can induce polymerization of STING monomers.
2. A method for preparing the chemotherapeutic drug-polymer conjugate capable of triggering active transcellular transport according to claim 1, It is characterized in that The following steps are involved: (1) reacting 2,2'-dithiodiethanol and methacryloyl chloride at room temperature in the presence of an acid binding agent to obtain a colorless oily product SS-MA; (2) reacting the SS-MA described in step (1) with 4-nitrophenyl chloroformate at room temperature in the presence of a catalyst and an acid binding agent to obtain a light yellow oily product SS-MA-PNP; (3) reacting the SS-MA-PNP described in step (2) and gemcitabine whose hydroxyl group is protected by tert-butyldimethylsilyl chloride (TBS) at room temperature in the presence of a catalyst and an acid binding agent to obtain a light yellow solid product, Gem-SS-MA-TBS; (4) removing TBS from the Gem-SS-MA-TBS described in step (3) in an ice bath under the action of acetic acid and tetrabutylammonium fluoride to obtain a white solid product Gem-SS-MA; (5) acylation reaction of methacryloyl chloride and 2-(hexamethyleneimino)ethanol in the presence of an acid-binding agent to obtain a yellow oily product HMI-MA; (6) 2-(N,N-diethylamino)ethyl methacrylate was polymerized to obtain a light yellow viscous liquid product PDEA; PDEA was dissolved in 30% H 2 O 2 The solution was shaken at room temperature to obtain a flocculent white solid product PODEA; (7) polymerizing the Gem-SS-MA described in step (4), the HMI-MA described in step (5), and the PODEA described in step (6) to obtain a light yellow flocculent solid product PODEA-Gem-HMI, which is the above-mentioned chemotherapeutic drug-polymer conjugate that can trigger active transcellular transport; The catalyst is 4-dimethylaminopyridine, and the acid binding agent is triethylamine.
3. The method for preparing the chemotherapeutic drug-polymer conjugate capable of triggering active transcellular transport according to claim 2, It is characterized in that Step (1) Firstly, 2,2'-dithiodiethanol and an acid binding agent are dissolved in an organic solvent and cooled to 0°C. A mixture of methacryloyl chloride and an organic solvent is added dropwise within 30 minutes. After 1 hour, the reaction system is returned to room temperature and the reaction is continued by stirring for 12 hours.
4. The method for preparing the chemotherapeutic drug-polymer conjugate capable of triggering active transcellular transport according to claim 3, It is characterized in that In step (1), the molar ratio of 2,2'-dithiodiethanol, triethylamine and methacryloyl chloride is 1:(1-2):(1-1.5).
5. The method for preparing the chemotherapeutic drug-polymer conjugate capable of triggering active transcellular transport according to claim 3, It is characterized in that The organic solvent is tetrahydrofuran.
6. A method for preparing a chemotherapeutic drug-polymer conjugate capable of triggering active transcellular transport according to claim 2, It is characterized in that In step (2), SS-MA, 4-dimethylaminopyridine and triethylamine are first dissolved in an organic solvent and cooled to 0°C. A mixture of 4-nitrophenyl chloroformate and the organic solvent is added dropwise within 1 hour. After 1 hour, the reaction system is returned to room temperature and the reaction is continued by stirring for 12 hours.
7. A method for preparing a chemotherapeutic drug-polymer conjugate capable of triggering active transcellular transport according to claim 6, It is characterized in that The molar ratio of the SS-MA, 4-nitrophenyl chloroformate, 4-dimethylaminopyridine and triethylamine is 1:(1-1.5):(0.01-0.05):(1.2-1.8).
8. The method for preparing the chemotherapeutic drug-polymer conjugate capable of triggering active transcellular transport according to claim 2, It is characterized in that The molar ratio of SS-MA-PNP, gemcitabine whose hydroxyl group is protected by tert-butyldimethylsilyl chloride, 4-dimethylaminopyridine and triethylamine in step (3) is 1:(1-2):(0.01-0.05):(1-2.5).
9. The method for preparing the chemotherapeutic drug-polymer conjugate capable of triggering active transcellular transport according to claim 2, It is characterized in that In step (3), SS-MA-PNP, 4-dimethylaminopyridine and triethylamine are first dissolved in dichloromethane and cooled to 0°C. A mixture of gemcitabine whose hydroxyl group is protected by tert-butyldimethylsilyl chloride and dichloromethane is added dropwise within 30 minutes. After 1 hour, the reaction system is returned to room temperature and the reaction is continued by stirring for 6 hours.
10. The method for preparing the chemotherapeutic drug-polymer conjugate capable of triggering active transcellular transport according to claim 2, It is characterized in that In step (4), Gem-SS-MA-TBS is first dissolved in an organic solvent, and then a mixture of acetic acid, tetrabutylammonium fluoride and the organic solvent is added, and the mixture is stirred in an ice bath for 5 hours.
11. A method for preparing a chemotherapeutic drug-polymer conjugate capable of triggering active transcellular transport according to claim 10, It is characterized in that In step (4), the molar ratio of Gem-SS-MA-TBS, acetic acid and tetrabutylammonium fluoride is 1:(2-8):(2-5).
12. The method for preparing the chemotherapeutic drug-polymer conjugate capable of triggering active transcellular transport according to claim 2, It is characterized in that The mass ratio of 2-(hexamethyleneimino)ethanol, methacryloyl chloride and triethylamine in step (5) is 1:(1-1.5):(1-2).
13. A method for preparing a chemotherapeutic drug-polymer conjugate capable of triggering active transcellular transport according to claim 12, It is characterized in that In step (5), 2-(hexamethyleneimino)ethanol and triethylamine are first dissolved in an organic solvent and cooled to 0°C, and a mixture of methacryloyl chloride and an organic solvent is added dropwise within 30 minutes. After 1 hour, the reaction system is returned to room temperature and the reaction is continued by stirring for 12 hours.
14. The method for preparing the chemotherapeutic drug-polymer conjugate capable of triggering active transcellular transport according to claim 2, It is characterized in that In step (6), 2-(N,N-diethylamino)ethyl methacrylate is subjected to ATRP polymerization reaction at 40° C. with ethyl 2-bromoisobutyrate as initiator and anhydrous methanol as solvent in the presence of a catalytic system of 2,2′-bipyridine and cuprous bromide for 12 hours.
15. The method for preparing the chemotherapeutic drug-polymer conjugate capable of triggering active transcellular transport according to claim 14, It is characterized in that The mass ratio of ethyl 2-bromoisobutyrate, 2-(N,N-diethylamino)ethyl methacrylate, 2,2'-bipyridine and cuprous bromide is 1:(10-60):(0.5-3):(0.2-1).
16. The method for preparing the chemotherapeutic drug-polymer conjugate capable of triggering active transcellular transport according to claim 2, It is characterized in that In step (7), the Gem-SS-MA described in step (4), the HMI-MA described in step (5), and the PODEA described in step (6) are subjected to ATRP polymerization in the presence of 2,2'-bipyridine and cuprous bromide catalyst system and anhydrous N,N-dimethylformamide as solvent at 40° C. for 12 hours.
17. The method for preparing the chemotherapeutic drug-polymer conjugate capable of triggering active transcellular transport according to claim 16, It is characterized in that The molar ratio of PODEA, HMI-MA and Gem-SS-MA is (3-8):(5-20):1; the molar ratio of PODEA, 2,2'-bipyridine and cuprous bromide is 1:(0.5-3):(0.2-1).
18. A drug-loaded polymer nanoparticle prepared from the chemotherapeutic drug-polymer conjugate capable of triggering active transcellular transport according to claim 1 or the chemotherapeutic drug-polymer conjugate capable of triggering active transcellular transport prepared by the method according to any one of claims 2 to 17, It is characterized in that The nanoparticles also encapsulate small molecule hydrophobic FAK inhibitors, with a drug loading of 2%-20%; and the particle size of the nanoparticles is 30-150nm.
19. The drug-loaded polymer nanoparticles according to claim 18, It is characterized in that The small molecule hydrophobic FAK inhibitor is defatinib, PND-1186, PF-431396, PF-562271, PF-573228 or TAE226.
20. The method for preparing the drug-loaded polymer nanoparticles according to claim 19, It is characterized in that The following steps are involved: The above-mentioned chemotherapeutic drug-polymer conjugate PODEA-Gem-HMI that can trigger active transcellular transport and the small molecule hydrophobic FAK inhibitor are dissolved in a polar organic solvent, then dropped into PBS buffer under vigorous stirring, and continued to be vigorously stirred. After centrifugation and dialysis, drug-loaded polymer nanoparticles that can trigger active transcellular transport are obtained.
21. The method for preparing drug-loaded polymer nanoparticles according to claim 20, It is characterized in that The polar organic solvent is selected from methanol, acetonitrile, N,N-dimethylformamide or dimethyl sulfoxide; the stirring speed is>150rpm.
